<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4247">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272232</url>
  </required_header>
  <id_info>
    <org_study_id>NN8022-1922</org_study_id>
    <secondary_id>2008-002199-88</secondary_id>
    <secondary_id>U1111-1118-7963</secondary_id>
    <nct_id>NCT01272232</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes</brief_title>
  <official_title>Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Africa, Asia, Europe and the United States of America (USA).

      The aim of this trial is to investigate the potential of liraglutide to induce and maintain
      weight loss in overweight or obese subjects with type 2 diabetes. Treatment will be added
      onto subject's pre-trial background diabetes treatment of either diet and exercise only or
      single compound oral antidiabetic drug (OAD) treatment (metformin, sulphonylurea [SU] or
      glitazone) or combination OAD treatment (metformin, sulphonylurea or glitazone). The
      duration of the trial will be 56 weeks followed by a 12 week observational follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change (%) From Baseline in Body Weight (Fasting)</measure>
    <time_frame>Week 0, week 56</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Losing at Least 5% of Baseline Body Weight</measure>
    <time_frame>at 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects Losing More Than 10% of Baseline Body Weight</measure>
    <time_frame>at 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change (%-Points) From Baseline in HbA1c (Glycosylated Haemoglobin A1c)</measure>
    <time_frame>Week 0, week 56</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in HbA1c (%-points) was calculated as the difference between the HbA1c (%) at Week 0 and Week 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Reaching Target HbA1c Below 7%</measure>
    <time_frame>at 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Reaching Target HbA1c Below or Equal to 6.5%</measure>
    <time_frame>at 56 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference</measure>
    <time_frame>Week 0, week 56</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (%) From Baseline in Body Weight (Fasting)</measure>
    <time_frame>Week 0, week 68</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (%) From Week 56 to 68 in Body Weight (Fasting)</measure>
    <time_frame>Week 56, week 68</time_frame>
    <safety_issue>No</safety_issue>
    <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference</measure>
    <time_frame>Week 0, week 68</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 56 to 68 in Waist Circumference</measure>
    <time_frame>Week 56, week 68</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypoglycaemic Episodes</measure>
    <time_frame>Weeks 0-56</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hypoglycaemic episodes were classified according to American Diabetes Association (ADA) definitions as well as to the Novo Nordisk definition of a minor hypoglycaemic event (blood glucose level below approximately 2.8 mmol/L [50 mg/dL] or plasma glucose level below 3.1 mmol/L [56 mg/dL]).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">846</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lira 3.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira 1.8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.</description>
    <arm_group_label>Lira 3.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.</description>
    <arm_group_label>Lira 1.8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained

          -  Subjects diagnosed with type 2 diabetes and treated with either diet and exercise
             alone, metformin, sulphonylurea, glitazone as single agent therapy or a combination
             of the previously mentioned compounds

          -  HbA1c 7.0-10.0% (both inclusive)

          -  Body Mass Index (BMI) at least 27.0 kg/m^2

          -  Stable body weight

          -  Preceding failed dietary effort

        Exclusion Criteria:

          -  Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl
             peptidase-4 (DPP-4) inhibitors or insulin within the last 3 months

          -  Known proliferative retinopathy or maculopathy

          -  History of acute or chronic pancreatitis

          -  Obesity induced by drug treatment

          -  Use of approved weight lowering pharmacotherapy

          -  Previous surgical treatment of obesity

          -  History of major depressive disorder or suicide attempt

          -  Uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or
             diastolic blood pressure above or equal to 100 mmHg)

          -  Screening calcitonin of 50 ng/L or above

          -  Familial or personal history of multiple endocrine neoplasia type 2 (MEN2) or
             familial medullary thyroid carcinoma (FMTC)

          -  Personal history of non-familial medullary thyroid carcinoma
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Vestavia</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <zip>80005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Meridien</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-5975</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034-7661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416-2699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755-8050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Moncks Corner</city>
        <state>South Carolina</state>
        <zip>29461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207-5209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>35152</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göteborg</city>
        <zip>417 17</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hatay</city>
        <zip>31040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 7, 2015</lastchanged_date>
  <firstreceived_date>January 6, 2011</firstreceived_date>
  <firstreceived_results_date>January 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 126 sites in 9 countries participated: France (7), Germany (10), Israel (5), South Africa (6), Spain (8), Sweden (5), Turkey (3), United Kingdom (15), United States (67).</recruitment_details>
      <pre_assignment_details>If eligible based on screened assessments, subjects were randomised to 1 of the 3 treatment arms in a 2:1:1 manner (liraglutide 3.0 mg, liraglutide 1.8 mg and placebo, respectively).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide 3.0 mg</title>
          <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
        </group>
        <group group_id="P2">
          <title>Liraglutide 1.8 mg</title>
          <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
        </group>
        <group group_id="P3">
          <title>Liraglutide Placebo</title>
          <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Weeks 0-56</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="423"/>
                <participants group_id="P2" count="211"/>
                <participants group_id="P3" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed</title>
              <participants_list>
                <participants group_id="P1" count="422">1 subject dropped out after randomisation and before exposure to trial drug.</participants>
                <participants group_id="P2" count="210">1 subject dropped out after randomisation and before exposure to trial drug.</participants>
                <participants group_id="P3" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="324"/>
                <participants group_id="P2" count="164"/>
                <participants group_id="P3" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Off Drug Follow-up Period (Weeks 56-68)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="324"/>
                <participants group_id="P2" count="164"/>
                <participants group_id="P3" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="310"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide 3.0 mg</title>
          <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
        </group>
        <group group_id="B2">
          <title>Liraglutide 1.8 mg</title>
          <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
        </group>
        <group group_id="B3">
          <title>Liraglutide Placebo</title>
          <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="423"/>
                <measurement group_id="B2" value="211"/>
                <measurement group_id="B3" value="212"/>
                <measurement group_id="B4" value="846"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55.0" spread="10.8"/>
                <measurement group_id="B2" value="54.9" spread="10.7"/>
                <measurement group_id="B3" value="54.7" spread="9.8"/>
                <measurement group_id="B4" value="54.9" spread="10.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="203"/>
                <measurement group_id="B2" value="103"/>
                <measurement group_id="B3" value="115"/>
                <measurement group_id="B4" value="421"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="220"/>
                <measurement group_id="B2" value="108"/>
                <measurement group_id="B3" value="97"/>
                <measurement group_id="B4" value="425"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="24"/>
                <measurement group_id="B4" value="87"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="375"/>
                <measurement group_id="B2" value="194"/>
                <measurement group_id="B3" value="187"/>
                <measurement group_id="B4" value="756"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="4"/>
                <measurement group_id="B4" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="27"/>
                <measurement group_id="B4" value="98"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="353"/>
                <measurement group_id="B2" value="177"/>
                <measurement group_id="B3" value="175"/>
                <measurement group_id="B4" value="705"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age group</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>18- &lt; 40 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="13"/>
                <measurement group_id="B4" value="66"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>40- &lt; 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="300"/>
                <measurement group_id="B2" value="162"/>
                <measurement group_id="B3" value="161"/>
                <measurement group_id="B4" value="623"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>65- &lt; 75 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="74"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="36"/>
                <measurement group_id="B4" value="142"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;= 75 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Fasting body weight</title>
          <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="105.7" spread="21.9"/>
                <measurement group_id="B2" value="105.8" spread="21.0"/>
                <measurement group_id="B3" value="106.5" spread="21.3"/>
                <measurement group_id="B4" value="105.9" spread="21.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>Height was recorded without shoes.</description>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1.69" spread="0.11"/>
                <measurement group_id="B2" value="1.69" spread="0.10"/>
                <measurement group_id="B3" value="1.69" spread="0.10"/>
                <measurement group_id="B4" value="1.69" spread="0.10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.1" spread="6.5"/>
                <measurement group_id="B2" value="37.0" spread="6.9"/>
                <measurement group_id="B3" value="37.4" spread="7.1"/>
                <measurement group_id="B4" value="37.1" spread="6.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) group</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>25.0-29.9 kg/m^2 - pre-obese</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="30"/>
                <measurement group_id="B4" value="116"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>30.0-34.9 kg/m^2 - obese class I</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="139"/>
                <measurement group_id="B2" value="62"/>
                <measurement group_id="B3" value="59"/>
                <measurement group_id="B4" value="260"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>35.0-39.9 kg/m^2 - obese class II</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="108"/>
                <measurement group_id="B2" value="50"/>
                <measurement group_id="B3" value="60"/>
                <measurement group_id="B4" value="218"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;40.0 kg/m^2 - obese class III</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="124"/>
                <measurement group_id="B2" value="65"/>
                <measurement group_id="B3" value="63"/>
                <measurement group_id="B4" value="252"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>HbA1c (glycosylated haemoglobin)</title>
          <units>Percent (%) glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7.9" spread="0.8"/>
                <measurement group_id="B2" value="8.0" spread="0.8"/>
                <measurement group_id="B3" value="7.9" spread="0.8"/>
                <measurement group_id="B4" value="7.9" spread="0.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8.8" spread="1.9"/>
                <measurement group_id="B2" value="8.9" spread="2.0"/>
                <measurement group_id="B3" value="8.6" spread="1.8"/>
                <measurement group_id="B4" value="8.8" spread="1.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Co-morbid hypertension</title>
          <description>Presence or absence of untreated or treated hypertension</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Present</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="293"/>
                <measurement group_id="B2" value="148"/>
                <measurement group_id="B3" value="145"/>
                <measurement group_id="B4" value="586"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Absent</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="130"/>
                <measurement group_id="B2" value="63"/>
                <measurement group_id="B3" value="67"/>
                <measurement group_id="B4" value="260"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Co-morbid dyslipidaemia</title>
          <description>Presence or absence of untreated or treated dyslipidaemia</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Present</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="295"/>
                <measurement group_id="B2" value="143"/>
                <measurement group_id="B3" value="126"/>
                <measurement group_id="B4" value="564"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Absent</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="128"/>
                <measurement group_id="B2" value="68"/>
                <measurement group_id="B3" value="86"/>
                <measurement group_id="B4" value="282"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7.54" spread="5.65"/>
                <measurement group_id="B2" value="7.43" spread="5.16"/>
                <measurement group_id="B3" value="6.71" spread="5.07"/>
                <measurement group_id="B4" value="7.30" spread="5.39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change (%) From Baseline in Body Weight (Fasting)</title>
        <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
        <time_frame>Week 0, week 56</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last Observation Carried Forward (LOCF) data. Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="412"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="211"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change (%) From Baseline in Body Weight (Fasting)</title>
            <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-5.9" spread="5.5"/>
                  <measurement group_id="O2" value="-4.6" spread="5.5"/>
                  <measurement group_id="O3" value="-2.0" spread="4.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 3 co-primary endpoints (Outcome Measures 1, 2 and 3) were ranked (#1, 2, 3); hypotheses of no difference were tested in a hierarchical manner. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-3.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.84</ci_lower_limit>
            <ci_upper_limit>-3.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 3 co-primary endpoints (Outcome Measures 1, 2 and 3) were ranked (#1, 2, 3); hypotheses of no difference were tested in a hierarchical manner. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-2.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.63</ci_lower_limit>
            <ci_upper_limit>-1.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 3 co-primary endpoints (Outcome Measures 1, 2 and 3) were ranked (#1, 2, 3); hypotheses of no difference were tested in a hierarchical manner. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0024</p_value>
            <p_value_desc>Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.23</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Losing at Least 5% of Baseline Body Weight</title>
        <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
        <time_frame>at 56 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last Observation Carried Forward (LOCF) data. Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="412"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="211"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Subjects Losing at Least 5% of Baseline Body Weight</title>
            <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49.9"/>
                  <measurement group_id="O2" value="35.6"/>
                  <measurement group_id="O3" value="13.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.1"/>
                  <measurement group_id="O2" value="64.4"/>
                  <measurement group_id="O3" value="86.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 3 co-primary endpoints (Outcome Measures 1, 2 and 3) were ranked (#1, 2, 3); hypotheses of no difference were tested in a hierarchical manner. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.34</ci_lower_limit>
            <ci_upper_limit>10.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 3 co-primary endpoints (Outcome Measures 1, 2 and 3) were ranked (#1, 2, 3); hypotheses of no difference were tested in a hierarchical manner. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.24</ci_lower_limit>
            <ci_upper_limit>6.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 3 co-primary endpoints (Outcome Measures 1, 2 and 3) were ranked (#1, 2, 3); hypotheses of no difference were tested in a hierarchical manner. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0008</p_value>
            <p_value_desc>Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>2.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Losing More Than 10% of Baseline Body Weight</title>
        <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
        <time_frame>at 56 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last Observation Carried Forward (LOCF) data. Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="412"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="211"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Subjects Losing More Than 10% of Baseline Body Weight</title>
            <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.4"/>
                  <measurement group_id="O2" value="14.4"/>
                  <measurement group_id="O3" value="4.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.6"/>
                  <measurement group_id="O2" value="85.6"/>
                  <measurement group_id="O3" value="95.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 3 co-primary endpoints (Outcome Measures 1, 2 and 3) were ranked (#1, 2, 3); hypotheses of no difference were tested in a hierarchical manner. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.48</ci_lower_limit>
            <ci_upper_limit>14.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The 3 co-primary endpoints (Outcome Measures 1, 2 and 3) were ranked (#1, 2, 3); hypotheses of no difference were tested in a hierarchical manner. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0008</p_value>
            <p_value_desc>Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.75</ci_lower_limit>
            <ci_upper_limit>8.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The 3 co-primary endpoints (Outcome Measures 1, 2 and 3) were ranked (#1, 2, 3); hypotheses of no difference were tested in a hierarchical manner. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0099</p_value>
            <p_value_desc>Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>2.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change (%-Points) From Baseline in HbA1c (Glycosylated Haemoglobin A1c)</title>
        <description>Change in HbA1c (%-points) was calculated as the difference between the HbA1c (%) at Week 0 and Week 56.</description>
        <time_frame>Week 0, week 56</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last Observation Carried Forward (LOCF) data. Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="412"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="211"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change (%-Points) From Baseline in HbA1c (Glycosylated Haemoglobin A1c)</title>
            <description>Change in HbA1c (%-points) was calculated as the difference between the HbA1c (%) at Week 0 and Week 56.</description>
            <units>percentage point change of HbA1c</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.3" spread="0.9"/>
                  <measurement group_id="O2" value="-1.1" spread="1.0"/>
                  <measurement group_id="O3" value="-0.3" spread="0.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>-0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0125</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Reaching Target HbA1c Below 7%</title>
        <time_frame>at 56 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last Observation Carried Forward (LOCF) data. Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="412"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="211"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Subjects Reaching Target HbA1c Below 7%</title>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="69.2"/>
                  <measurement group_id="O2" value="66.7"/>
                  <measurement group_id="O3" value="27.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.8"/>
                  <measurement group_id="O2" value="33.3"/>
                  <measurement group_id="O3" value="72.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.74</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.76</ci_lower_limit>
            <ci_upper_limit>12.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5319</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Reaching Target HbA1c Below or Equal to 6.5%</title>
        <time_frame>at 56 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last Observation Carried Forward (LOCF) data. Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="412"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="211"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Subjects Reaching Target HbA1c Below or Equal to 6.5%</title>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.5"/>
                  <measurement group_id="O2" value="45.6"/>
                  <measurement group_id="O3" value="15.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.5"/>
                  <measurement group_id="O2" value="54.4"/>
                  <measurement group_id="O3" value="85.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.05</ci_lower_limit>
            <ci_upper_limit>15.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.59</ci_lower_limit>
            <ci_upper_limit>9.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0142</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference</title>
        <time_frame>Week 0, week 56</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last Observation Carried Forward (LOCF) data. Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="412"/>
                  <measurement group_id="O2" value="204"/>
                  <measurement group_id="O3" value="211"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Waist Circumference</title>
            <units>cm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-6.1" spread="6.5"/>
                  <measurement group_id="O2" value="-4.8" spread="5.6"/>
                  <measurement group_id="O3" value="-2.7" spread="5.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-3.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.20</ci_lower_limit>
            <ci_upper_limit>-2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0004</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-2.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.20</ci_lower_limit>
            <ci_upper_limit>-0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0224</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.16</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change (%) From Baseline in Body Weight (Fasting)</title>
        <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
        <time_frame>Week 0, week 68</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="324"/>
                  <measurement group_id="O2" value="164"/>
                  <measurement group_id="O3" value="140"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change (%) From Baseline in Body Weight (Fasting)</title>
            <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-4.7" spread="5.0"/>
                  <measurement group_id="O2" value="-3.6" spread="5.7"/>
                  <measurement group_id="O3" value="-2.7" spread="5.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0002</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-2.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.32</ci_lower_limit>
            <ci_upper_limit>-1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0725</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.51</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0717</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.02</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change (%) From Week 56 to 68 in Body Weight (Fasting)</title>
        <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
        <time_frame>Week 56, week 68</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last Observation Carried Forward (LOCF) data. Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="324"/>
                  <measurement group_id="O2" value="164"/>
                  <measurement group_id="O3" value="140"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change (%) From Week 56 to 68 in Body Weight (Fasting)</title>
            <description>Weight was recorded to the nearest 0.1 kg for a subject in the fasting state with an empty bladder, without shoes and only wearing light clothing. The same calibrated scale was used throughout the trial.</description>
            <units>percent change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" spread="2.9"/>
                  <measurement group_id="O2" value="2.0" spread="2.9"/>
                  <measurement group_id="O3" value="-0.1" spread="2.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference</title>
        <time_frame>Week 0, week 68</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="324"/>
                  <measurement group_id="O2" value="164"/>
                  <measurement group_id="O3" value="140"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Waist Circumference</title>
            <units>cm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-5.7" spread="6.3"/>
                  <measurement group_id="O2" value="-4.4" spread="6.0"/>
                  <measurement group_id="O3" value="-3.2" spread="6.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-2.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.75</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0457</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-1.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.92</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of no difference. Fixed factors: treatment, country, sex, background treatment, baseline HbA1c stratum, background treatment/HbA1c-stratum-interaction; covariate: baseline value.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0961</p_value>
            <p_value_desc>p values are 2-sided; 5% pre-defined significance level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Treatment contrast</param_type>
            <param_value>-1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.22</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 56 to 68 in Waist Circumference</title>
        <time_frame>Week 56, week 68</time_frame>
        <safety_issue>No</safety_issue>
        <population>Last Observation Carried Forward (LOCF) data. Full analysis set, comprising all randomised subjects who had been exposed to at least 1 dose of trial product and with at least 1 post-randomisation assessment of any efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="324"/>
                  <measurement group_id="O2" value="164"/>
                  <measurement group_id="O3" value="140"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Week 56 to 68 in Waist Circumference</title>
            <units>cm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.21" spread="3.94"/>
                  <measurement group_id="O2" value="1.02" spread="3.55"/>
                  <measurement group_id="O3" value="-0.22" spread="3.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypoglycaemic Episodes</title>
        <description>Hypoglycaemic episodes were classified according to American Diabetes Association (ADA) definitions as well as to the Novo Nordisk definition of a minor hypoglycaemic event (blood glucose level below approximately 2.8 mmol/L [50 mg/dL] or plasma glucose level below 3.1 mmol/L [56 mg/dL]).</description>
        <time_frame>Weeks 0-56</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety analysis set, comprising all randomised subjects who had been exposed to at least one dose of trial product.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide 3.0 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O2">
            <title>Liraglutide 1.8 mg</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
          <group group_id="O3">
            <title>Liraglutide Placebo</title>
            <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="422"/>
                  <measurement group_id="O2" value="210"/>
                  <measurement group_id="O3" value="212"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Hypoglycaemic Episodes</title>
            <description>Hypoglycaemic episodes were classified according to American Diabetes Association (ADA) definitions as well as to the Novo Nordisk definition of a minor hypoglycaemic event (blood glucose level below approximately 2.8 mmol/L [50 mg/dL] or plasma glucose level below 3.1 mmol/L [56 mg/dL]).</description>
            <units>Episodes/100 years of patient exposure</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Minor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ADA: Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ADA: Documented, symptomatic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                  <measurement group_id="O2" value="95"/>
                  <measurement group_id="O3" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ADA: Asymptomatic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="142"/>
                  <measurement group_id="O3" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ADA: Probable, symptomatic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ADA: Relative</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ADA: Unclassifiable</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded for up to 68 weeks.</time_frame>
      <desc>Safety Analysis Set comprising all randomised subjects who had been exposed to at least one dose of trial product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide 3.0 mg</title>
          <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 3.0 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 3.0 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
        </group>
        <group group_id="E2">
          <title>Liraglutide 1.8 mg</title>
          <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide, titrated from a starting dose of 0.6 mg in weekly increments of 0.6 mg to the target dose of 1.8 mg. In the 12-week follow-up period, treatment was discontinued. In addition to liraglutide 1.8 mg treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
        </group>
        <group group_id="E3">
          <title>Liraglutide Placebo</title>
          <description>Exposed subjects received 56 weeks of once-daily subcutaneous (s.c.) injections with liraglutide placebo. In the 12-week follow-up period, treatment was discontinued. In addition to placebo treatment, subjects were instructed to follow a hypocaloric diet and an exercise programme. Pre-trial treatment with metformin, glitazone or sulphonorylureas (SU) was continued throughout the trial (open-label) at unchanged dose, expect for SU that was reduced by 50%.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcitonin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Nasal operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="422"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="422"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="361" subjects_at_risk="422"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="164" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="422"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="26" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="422"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="78" subjects_affected="68" subjects_at_risk="422"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="210"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="173" subjects_affected="108" subjects_at_risk="422"/>
                <counts group_id="E2" events="50" subjects_affected="37" subjects_at_risk="210"/>
                <counts group_id="E3" events="35" subjects_affected="27" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="59" subjects_affected="47" subjects_at_risk="422"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="422"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="210"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="208" subjects_affected="138" subjects_at_risk="422"/>
                <counts group_id="E2" events="84" subjects_affected="66" subjects_at_risk="210"/>
                <counts group_id="E3" events="34" subjects_affected="29" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="113" subjects_affected="66" subjects_at_risk="422"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="210"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="45" subjects_affected="35" subjects_at_risk="422"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="33" subjects_affected="19" subjects_at_risk="422"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="422"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="422"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="134" subjects_affected="88" subjects_at_risk="422"/>
                <counts group_id="E2" events="46" subjects_affected="34" subjects_at_risk="210"/>
                <counts group_id="E3" events="54" subjects_affected="41" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="422"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E3" events="22" subjects_affected="18" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="49" subjects_affected="40" subjects_at_risk="422"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="210"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="34" subjects_affected="19" subjects_at_risk="422"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="56" subjects_affected="50" subjects_at_risk="422"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="44" subjects_affected="40" subjects_at_risk="422"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="210"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="981" subjects_affected="187" subjects_at_risk="422"/>
                <counts group_id="E2" events="429" subjects_affected="84" subjects_at_risk="210"/>
                <counts group_id="E3" events="154" subjects_affected="59" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="30" subjects_at_risk="422"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="210"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="67" subjects_affected="42" subjects_at_risk="422"/>
                <counts group_id="E2" events="36" subjects_affected="27" subjects_at_risk="210"/>
                <counts group_id="E3" events="27" subjects_affected="20" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="422"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="422"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="39" subjects_affected="30" subjects_at_risk="422"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="125" subjects_affected="66" subjects_at_risk="422"/>
                <counts group_id="E2" events="42" subjects_affected="26" subjects_at_risk="210"/>
                <counts group_id="E3" events="40" subjects_affected="29" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="422"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="422"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk reserves the right not to release data until specified milestones are available. This includes the right not to release interim results from clinical trials, as such results may lead to conclusions that are later proven incorrect. At the end of the trial, one or more manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to briefly postpone publication or communication to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
